Company: OSRH
Filing Date: 2025-01-29
Form Type: S-4/A
Source: 0001213900-25-007923
Chunk: 512

Company: OSR Holdings, Inc.
Filing Date: 2025-01-29
Form: S-4/A
Chunk 512
---
 |  66 |     | Independent Director, Compensation Committee Member                                                         |
| Seng Chin Mah                    |     |  65 |     | Independent Director, Compensation Committee Chair and Corporate Governance and Nomination Committee Member |
| Jin Whan Park**                  |     |  57 |     | Independent Director, Audit Committee Chair and Corporate Governance and Nomination Committee Member        |
| Sang Hyun Kim**                  |     |  54 |     | Independent Director, Compensation Committee Member                                                         |
| Hyuk Joo Jee                     |     |  57 |     | Independent Director, Audit Committee Member and Corporate Governance and Nomination Committee Member       |
| Joong Myung Cho                  |     |  75 |     | Independent Director, Corporate Governance and Nomination Committee Member                                  |

____________ *For Mr. Hwang’s, Mr. Kim’s and Mr. Bang’s biographies, please see “ Management of OSR Holdings — Executive Officers and Directorsof OSR Holdings.” **For Mr. Whang’s, Mr. Lee’s, Mr. Park’s and Mr. Kim’s biographies, please see “ Executive Officers and Directors of BLAC.” Non-Executive Directors Alcide Barberis, PhD, Independent Director Alcide Barberis will becomea Director upon Closing of the Business Combination. He is a biotech entrepreneur, Board Member and Executive with over 25 years of management experience in the biotechnology industry, and scientific experience in the private and public research sectors. He is currently CEO & Director of Mabylon AG (since 2017). Before joining Mabylon, he was CEO & President of Humabs BioMed, now a subsidiary of VIR Biotechnology (2013 -2016). His career has included senior positions at entrepreneurial startups (Co -Founderof ESBATech AG (1998) and Oncalis AG (2006) and senior Executive Management, R&D Management and Business Development positions. He has been member of the Board of Directors of ESBATech (now a Novartis company, 1998 -2004), Oncalis (2006 -2012) and EffRx Pharmaceuticals (2016 -2023), and he is currently (since March 2023) on the Board of Directors of Ontrack Biomedical. From 2016 through 2021 he was also Coordinator of the Startup Promotion Center of the University of Svizzera Italiana in Lugano, Switzerland. Dr. Barberis earned

322 a PhD in Molecular Biology and